Physician profile
John C Maize
NPI 1043299787
$10,942.90
in general payments reported to CMS, 2019-2025
34 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what 89% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $605 · 2021: $603 · 2022: $1,484 · 2023: $1,814 · 2024: $2,408 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,517 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,517.09 |
| Education | $219.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,383.95 | 2019-2025 | |
| Janssen Biotech, INC. | $1,274.41 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $1,073.38 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,038.78 | 2019-2025 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $762.37 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $739.94 | 2019-2025 | |
| Incyte Corporation | $720.29 | 2021-2025 | Opzelura |
| Amgen INC. | $659.38 | 2020-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $543.06 | 2019-2025 | |
| Lilly USA, LLC | $450.63 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $382.33 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $351.33 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $317.49 | 2019-2024 | Siliq, Targretin, Duobrii |
| Galderma Laboratories, L.P. | $252.65 | 2019-2025 | Nemluvio |
| Celgene Corporation | $139.06 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $111.22 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $107.05 | 2019-2025 | |
| Organon LLC | $100.04 | 2024-2025 | Hadlima |
| Almirall LLC | $97.82 | 2022-2025 | Klisyri |
| Genentech USA, INC. | $81.60 | 2019-2020 | |
| Biofrontera INC. | $62.52 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Dermavant Sciences, INC. | $57.75 | 2023 | Vtama |
| Sandoz INC. | $33.26 | 2023-2025 | Hyrimoz |
| Myriad Genetic Laboratories, INC. | $29.96 | 2021 | |
| Organogenesis INC. | $24.64 | 2022 | |
| Therakos LLC | $21.75 | 2025 | Uvadex |
| Kyowa Kirin, INC. | $21.56 | 2019 | |
| Prugen, INC. Pharmaceuticals | $19.10 | 2019 | |
| Epi Health, LLC | $17.66 | 2021 | |
| Vyne Pharmaceuticals INC. | $15.91 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.48 | 2021 | |
| Strata Skin Sciences, INC. | $13.15 | 2024 | Xtrac |
| Bioventus LLC | $12.30 | 2022 | |
| Aclaris Therapeutics, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Maize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.